Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Rheumatological Diseases in HIV Infection

Author(s): Liberato Giardullo*, Ada Corrado*, Nicola Maruotti, Cinzia Rotondo* and Francesco Paolo Cantatore*

Volume 17, Issue 3, 2021

Published on: 08 December, 2020

Page: [271 - 282] Pages: 12

DOI: 10.2174/1573397116999201208213717

Price: $65

Abstract

A review of the available literature was performed in order to summarize the pathogenic and clinical connections between HIV infection and rheumatological syndromes. The increasing life expectancy during human immunodeficiency virus (HIV) infection has led to the observation of many rheumatological manifestations over the years in these types of patients. Although the pathological mechanisms are still not fully understood, several rheumatological diseases have been more commonly observed in the general population, especially after the advent of highly active antiretroviral therapy (HAART), and sometimes clinical and serological findings are influenced by the underlying condition which defines a characteristic onset or development of the disease. Autoimmune diseases occur during specific stages of the HIV infection, depending on the underlying pathogenic mechanism being mainly influenced by the CD4+ cells count. Several rheumatological diseases show peculiar clinical manifestations influenced by the underlying HIV infection leading to specific features less commonly observed in the healthy population. Conversely to pathological findings, broadly, HIV-1-neutralizing antibodies (BnAb) observed in several autoimmune diseases, such as SLE, could play a protective role in HIV infection. It is important to evaluate the onset of autoimmune diseases in HIV patients in order to start the appropriate treatment to avoid harmful events. More studies are needed to enlighten the trend of autoimmune diseases during HIV infection. Pathogenic mechanisms and clinical manifestations of rheumatological diseases during HIV infection are discussed in this review.

Keywords: HIV, AIDS, HAART, autoimmune, rheumatology, arthritis.

Next »
Graphical Abstract

[1]
Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305(24): 1425-31.
[http://dx.doi.org/10.1056/NEJM198112103052401] [PMID: 6272109]
[2]
Follansbee SE, Busch DF, Wofsy CB, et al. An outbreak of Pneumocystis carinii pneumonia in homosexual men. Ann Intern Med 1982; 96(6 Pt 1): 705-13.
[http://dx.doi.org/10.7326/0003-4819-96-6-705] [PMID: 6283975]
[3]
Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71.
[http://dx.doi.org/10.1126/science.6189183] [PMID: 6189183]
[4]
Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 865-7.
[http://dx.doi.org/10.1126/science.6601823] [PMID: 6601823]
[5]
Coffin J, Haase A, Levy JA, et al. What to call the AIDS virus? Nature 1986; 321(6065): 10.
[http://dx.doi.org/10.1038/321010a0] [PMID: 3010128]
[6]
Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S. al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Statistics in medicine England 2003; 22: 573-93.
[7]
Gottlieb GS, Eholié SP, Nkengasong JN, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22(16): 2069-72.
[http://dx.doi.org/10.1097/QAD.0b013e32830edd44] [PMID: 18832869]
[8]
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18): 1173-80.
[http://dx.doi.org/10.1056/NEJM199411033311801] [PMID: 7935654]
[9]
Jaryal A, Raina R, Sarkar M, Sharma A. Manifestations of tuberculosis in HIV/AIDS patients and its relationship with CD4 count. Lung India 2011; 28(4): 263-6.
[http://dx.doi.org/10.4103/0970-2113.85687] [PMID: 22084539]
[10]
Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017; 4(8): e349-56.
[http://dx.doi.org/10.1016/S2352-3018(17)30066-8] [PMID: 28501495]
[11]
Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol 2007; 37(Suppl. 1): S94-S102.
[http://dx.doi.org/10.1002/eji.200737441] [PMID: 17972351]
[12]
Virot E, Duclos A, Adelaide L, et al. Autoimmune diseases and HIV infection: A cross-sectional study. Medicine (Baltimore) 2017; 96(4): e5769.
[http://dx.doi.org/10.1097/MD.0000000000005769] [PMID: 28121924]
[13]
Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005; 35(3): 166-74.
[http://dx.doi.org/10.1016/j.semarthrit.2005.03.007] [PMID: 16325657]
[14]
Plate A-M, Boyle BA. Musculoskeletal manifestations of HIV infection. AIDS Read 2003; 13(2): 62-76.
[15]
Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9(4): 235-45.
[http://dx.doi.org/10.1038/nri2524] [PMID: 19319142]
[16]
Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1(6): 329-37.
[http://dx.doi.org/10.1016/S1568-9972(02)00086-1] [PMID: 12848988]
[17]
Cohen AD, Shoenfeld Y. The viral-autoimmunity relationship. Viral Immunol 1995; 8(1): 1-9.
[http://dx.doi.org/10.1089/vim.1995.8.1] [PMID: 8546799]
[18]
Golding H, Robey FA, Gates FT III, et al. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II β 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients’ sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 1988; 167(3): 914-23.
[http://dx.doi.org/10.1084/jem.167.3.914] [PMID: 3127528]
[19]
Deas JE, Liu LG, Thompson JJ, et al. Reactivity of sera from systemic lupus erythematosus and Sjögren’s syndrome patients with peptides derived from human immunodeficiency virus p24 capsid antigen. Clin Diagn Lab Immunol 1998; 5(2): 181-5.
[http://dx.doi.org/10.1128/CDLI.5.2.181-185.1998] [PMID: 9521140]
[20]
Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200(6): 749-59.
[http://dx.doi.org/10.1084/jem.20040874] [PMID: 15365096]
[21]
Gosselin A, Monteiro P, Chomont N, et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 2010; 184(3): 1604-16.
[http://dx.doi.org/10.4049/jimmunol.0903058] [PMID: 20042588]
[22]
Alvarez Y, Tuen M, Shen G, et al. Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands. J Virol 2013; 87(19): 10843-54.
[http://dx.doi.org/10.1128/JVI.01838-13] [PMID: 23903844]
[23]
Guo H, Gao J, Taxman DJ, Ting JPY, Su L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J Biol Chem 2014; 289(31): 21716-26.
[http://dx.doi.org/10.1074/jbc.M114.566620] [PMID: 24939850]
[24]
Borges ÁH, O’Connor JL, Phillips AN, et al. Factors Associated With Plasma IL-6 Levels During HIV Infection. J Infect Dis 2015; 212(4): 585-95.
[http://dx.doi.org/10.1093/infdis/jiv123] [PMID: 25722296]
[25]
Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83(8): 3719-33.
[http://dx.doi.org/10.1128/JVI.01844-08] [PMID: 19176632]
[26]
Missé D, Yssel H, Trabattoni D, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 2007; 178(1): 407-15.
[http://dx.doi.org/10.4049/jimmunol.178.1.407] [PMID: 17182579]
[27]
Trovato M, Ruggeri RM, Sciacchitano S, et al. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. Immunobiology 2018; 223(3): 264-8.
[http://dx.doi.org/10.1016/j.imbio.2017.10.039] [PMID: 29055566]
[28]
Pellicano C, Leodori G, Innocenti GP, Gigante A, Rosato E. Pietro, Gigante A, Rosato E. Microbiome, autoimmune diseases and HIV infection: Friends or foes? Nutrients 2019; 11(11): 2629.
[http://dx.doi.org/10.3390/nu11112629] [PMID: 31684052]
[29]
Hima Bindu A, Naga Anusha P. Adverse effects of highly Active Anti-Retroviral Therapy (HAART). J Antivir Antiretrovir 2011; 3(4): 60-4.
[30]
Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50(5): 499-505.
[http://dx.doi.org/10.1097/QAI.0b013e31819c291b] [PMID: 19223782]
[31]
Freiberg MS, Chang CH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: Results from the veterans aging cohort study. JAMA Cardiol 2017; 2(5): 536-46.
[http://dx.doi.org/10.1001/jamacardio.2017.0264] [PMID: 28384660]
[32]
Currie PF, Goldman JH, Caforio ALP, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998; 79(6): 599-604.
[http://dx.doi.org/10.1136/hrt.79.6.599] [PMID: 10078089]
[33]
Winchester R, Bernstein DH, Fischer HD, Enlow R, Solomon G. The co-occurrence of Reiter’s syndrome and acquired immunodeficiency. Ann Intern Med 1987; 106(1): 19-26.
[http://dx.doi.org/10.7326/0003-4819-106-1-19] [PMID: 3789575]
[34]
Marquez J, Restrepo CS, Candia L, Berman A, Espinoza LR. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol 2004; 31(4): 741-6.
[PMID: 15088301]
[35]
Lebrun D, Hentzien M, Cuzin L, et al. Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. AIDS 2017; 31(15): 2159-66.
[http://dx.doi.org/10.1097/QAD.0000000000001603] [PMID: 28723711]
[36]
Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30(3): 147-66.
[http://dx.doi.org/10.1053/sarh.2000.16527] [PMID: 11124280]
[37]
Berman A, Espinoza LR, Diaz JD, et al. Rheumatic manifestations of human immunodeficiency virus infection. Am J Med 1988; 85(1): 59-64.
[http://dx.doi.org/10.1016/0002-9343(88)90503-7] [PMID: 3260453]
[38]
Breitbart W, McDonald MV, Rosenfeld B, et al. Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. Pain 1996; 68(2-3): 315-21.
[http://dx.doi.org/10.1016/S0304-3959(96)03215-0] [PMID: 9121820]
[39]
Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter’s syndrome: a disease continuum? Arthritis Rheum 1990; 33(10): 1574-8.
[http://dx.doi.org/10.1002/art.1780331016] [PMID: 2222538]
[40]
Rosenberg ZS, Norman A, Solomon G. Arthritis associated with HIV infection: Radiographic manifestations. Radiology 1989; 173(1): 171-6.
[http://dx.doi.org/10.1148/radiology.173.1.2781004] [PMID: 2781004]
[41]
Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. Best Pract Res Clin Rheumatol 2003; 17(2): 265-87.
[http://dx.doi.org/10.1016/S1521-6942(03)00003-2] [PMID: 12787525]
[42]
Yang JJ, Tsai MS, Sun HY, et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy. J Microbiol Immunol Infect 2015; 48(2): 130-6.
[http://dx.doi.org/10.1016/j.jmii.2013.08.002] [PMID: 24064287]
[43]
Varache S, Narbonne V, Jousse-Joulin S, et al. Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study. Arthritis Care Res (Hoboken) 2011; 63(11): 1565-70.
[http://dx.doi.org/10.1002/acr.20576] [PMID: 21954118]
[44]
Tarr G, Makda M, Musenge E, Tikly M. Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: A retrospective study in South Africans. J Rheumatol 2014; 41(8): 1645-9.
[http://dx.doi.org/10.3899/jrheum.130896] [PMID: 25028384]
[45]
Allroggen A, Frese A, Rahmann A, Gaubitz M, Husstedt IW, Evers S. HIV associated arthritis: Case report and review of the literature. Eur J Med Res 2005; 10(7): 305-8.
[PMID: 16055402]
[46]
Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol 1987; 123(12): 1622-32.
[http://dx.doi.org/10.1001/archderm.1987.01660360050012] [PMID: 3688903]
[47]
Lorenzo Castillo R, Zamora Racaza G, Dela CruzRoa F. Ostraceous and inverse psoriasis with psoriatic arthritis as thepresenting features of advanced HIV infection. Singapore Med J 2014.
[48]
Park M, Park MJ, Choi MS, et al. A case of ostraceous psoriasis with psoriatic arthritis in an AIDS patient. Indian J Dermatol 2018; 63(6): 512-4.
[PMID: 30504983]
[49]
Njobvu P, McGill P. Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol 2000; 27(7): 1699-702.
[PMID: 10914854]
[50]
Foulon G, Wislez M, Naccache J-M, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38(3): 418-25.
[http://dx.doi.org/10.1086/381094] [PMID: 14727215]
[51]
Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66(2): 144-50.
[http://dx.doi.org/10.1136/thx.2010.140319] [PMID: 21139119]
[52]
Lassalle S, Selva E, Hofman V, et al. Sarcoid-like lesions associated with the immune restoration inflammatory syndrome in AIDS: Absence of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Virchows Arch 2006; 449(6): 689-96.
[http://dx.doi.org/10.1007/s00428-006-0278-2] [PMID: 17043810]
[53]
Gomez V, Smith PR, Burack J, Daley R, Rosa U. Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2000; 31(5): 1278-80.
[http://dx.doi.org/10.1086/317422] [PMID: 11073764]
[54]
Sionidou M, Spyratos D, Chloros D, Sichletidis L. Interferon α-induced sarcoidosis to a patient with polycythemia vera. BMJ Case Rep 2011; 2011: bcr0120113740.
[http://dx.doi.org/10.1136/bcr.01.2011.3740] [PMID: 22696707]
[55]
Faurie P, Broussolle C, Zoulim F, Trepo C, Sève P. Sarcoidosis and hepatitis C: clinical description of 11 cases. Eur J Gastroenterol Hepatol 2010; 22(8): 967-72.
[http://dx.doi.org/10.1097/MEG.0b013e32833834bc] [PMID: 20216423]
[56]
Farkas A, Tonel G, Nestle FO. Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol 2008; 158(5): 921-9.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08508.x] [PMID: 18371115]
[57]
Doffman SR, Miller RF. Interstitial lung disease in HIV. Clin Chest Med 2013; 34(2): 293-306.
[http://dx.doi.org/10.1016/j.ccm.2013.01.012] [PMID: 23702178]
[58]
Almeida FA Jr, Sager JS, Eiger G. Coexistent sarcoidosis and HIV infection: An immunological paradox? J Infect 2006; 52(3): 195-201.
[http://dx.doi.org/10.1016/j.jinf.2005.05.009] [PMID: 16083964]
[59]
Haramati LB, Lee G, Singh A, Molina PL, White CS. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients. Radiology 2001; 218(1): 242-6.
[http://dx.doi.org/10.1148/radiology.218.1.r01ja25242] [PMID: 11152809]
[60]
Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology (Oxford) 2008; 47(7): 952-9.
[http://dx.doi.org/10.1093/rheumatology/ken132] [PMID: 18413346]
[61]
Sekigawa I, Lee S, Kaneko H, et al. The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus. Lupus 2000; 9(2): 155-6.
[http://dx.doi.org/10.1191/096120300678828136] [PMID: 10787016]
[62]
Bonsignori M, Wiehe K, Grimm SK, et al. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 2014; 124(4): 1835-43.
[http://dx.doi.org/10.1172/JCI73441] [PMID: 24614107]
[63]
Bonsignori M. Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design? Expert Rev Vaccines 2014; 13(11): 1271-3.
[http://dx.doi.org/10.1586/14760584.2014.938056] [PMID: 25017952]
[64]
Byrd VM, Sergent JS. Suppression of systemic lupus erythematosus by the human immunodeficiency virus. J Rheumatol 1996; 23(7): 1295-6.
[PMID: 8823711]
[65]
Fox RA, Isenberg DA. Human immunodeficiency virus infection in systemic lupus erythematosus. Arthritis Rheum 1997; 40(6): 1168-72.
[http://dx.doi.org/10.1002/art.1780400623] [PMID: 9182929]
[66]
Naovarat BS, Reveille JD, Salazar GA, Williams FM, Nguyen BY. Systemic lupus erythematosus in the setting of HIV-1 infection: A longitudinal analysis. Clin Rheumatol 2020; 39(2): 413-8.
[http://dx.doi.org/10.1007/s10067-019-04867-w] [PMID: 31897958]
[67]
Palacios R, Santos J. Human immunodeficiency virus infection and systemic lupus erythematosus. Int J STD AIDS 2004; 15(4): 277-8.
[http://dx.doi.org/10.1258/095646204773557857] [PMID: 15075026]
[68]
Yao Q, Frank M, Glynn M, Altman RD. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 2008; 26(5): 799-806.
[PMID: 19032811]
[69]
Patel N, Patel N, Khan T, Patel N, Espinoza LR. HIV infection and clinical spectrum of associated vasculitides. Curr Rheumatol Rep 2011; 13(6): 506-12.
[http://dx.doi.org/10.1007/s11926-011-0214-6] [PMID: 21989711]
[70]
Galrão L, Brites C, Atta ML, et al. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 2007; 26(11): 1825-30.
[http://dx.doi.org/10.1007/s10067-007-0581-6] [PMID: 17332976]
[71]
de Larrañaga G, Bottaro E, Martinuzzo M, et al. Thrombophilia in human immunodeficiency virus-infected patients with osteonecrosis: Is there a real connection? The first case-control study. Clin Appl Thromb Hemost 2009; 15(3): 340-7.
[http://dx.doi.org/10.1177/1076029607310217] [PMID: 18160564]
[72]
Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31(4): 256-63.
[http://dx.doi.org/10.1053/sarh.2002.28303] [PMID: 11836658]
[73]
Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis. Lupus 2018; 27(4): 572-83.
[http://dx.doi.org/10.1177/0961203317731532] [PMID: 28945149]
[74]
Sène D, Piette J-C, Cacoub P. Anticorps antiphospholipide, syndrome des anticorps antiphospholipides et infections virales. Rev Med Interne 2009; 30(2): 135-41. http://www.sciencedirect.com/science/article/pii/S0248866308006449
[http://dx.doi.org/10.1016/j.revmed.2008.05.020] [PMID: 18926604]
[75]
Martinez V, Diemert MC, Braibant M, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis 2009; 48(1): 123-32.
[http://dx.doi.org/10.1086/595013] [PMID: 19035778]
[76]
Silvestris F, Frassanito MA, Cafforio P, et al. Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Blood 1996; 87(12): 5185-95.
[http://dx.doi.org/10.1182/blood.V87.12.5185.bloodjournal87125185] [PMID: 8652832]
[77]
Stimmler MM, Quismorio FP Jr, McGehee WG, Boylen T, Sharma OP. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med 1989; 149(8): 1833-5.
[http://dx.doi.org/10.1001/archinte.1989.00390080091020] [PMID: 2504122]
[78]
Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with β2-GPI. J Autoimmun 1999; 13(3): 347-55.
[http://dx.doi.org/10.1006/jaut.1999.0324] [PMID: 10550222]
[79]
Ulirsch RC, Jaffe ES. Sjögren’s syndrome-like illness associated with the acquired immunodeficiency syndrome-related complex. Hum Pathol 1987; 18(10): 1063-8.
[http://dx.doi.org/10.1016/S0046-8177(87)80223-X] [PMID: 3653877]
[80]
Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 1990; 112(1): 3-10.
[http://dx.doi.org/10.7326/0003-4819-112-1-3] [PMID: 2136714]
[81]
Kordossis T, Paikos S, Aroni K, et al. Prevalence of Sjögren’s-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. Br J Rheumatol 1998; 37(6): 691-5.
[http://dx.doi.org/10.1093/rheumatology/37.6.691] [PMID: 9667626]
[82]
McArthur CP, Africa CWJ, Castellani WJ, et al. Salivary gland disease in HIV/AIDS and primary Sjögren’s syndrome: Analysis of collagen I distribution and histopathology in American and African patients. J Oral Pathol Med 2003; 32(9): 544-51.
[http://dx.doi.org/10.1034/j.1600-0714.2003.00159.x] [PMID: 12969229]
[83]
Basu D, Williams FM, Ahn CW, Reveille JD. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum 2006; 55(3): 466-72.
[http://dx.doi.org/10.1002/art.21980] [PMID: 16739215]
[84]
Manfredi R, Motta R, Patrono D, Calza L, Chiodo F, Boni P. A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy. AIDS 2002; 16(14): 1969-71.
[http://dx.doi.org/10.1097/00002030-200209270-00018] [PMID: 12351961]
[85]
Johnson RW, Williams FM, Kazi S, Dimachkie MM, Reveille JD. Human immunodeficiency virus-associated polymyositis: A longitudinal study of outcome. Arthritis Rheum 2003; 49(2): 172-8.
[http://dx.doi.org/10.1002/art.11002] [PMID: 12687507]
[86]
Hiniker A, Daniels BH, Margeta M. T-cell-mediated inflammatory myopathies in HIV-positive individuals: A histologic study of 19 cases. J Neuropathol Exp Neurol 2016; 75(3): 239-45.
[http://dx.doi.org/10.1093/jnen/nlv023] [PMID: 26843609]
[87]
Carroll MB, Holmes R. Dermatomyositis and HIV infection: Case report and review of the literature. Rheumatol Int 2011; 31(5): 673-9.
[http://dx.doi.org/10.1007/s00296-009-1231-x] [PMID: 19855968]
[88]
Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996; 119(Pt 6): 1887-93.
[http://dx.doi.org/10.1093/brain/119.6.1887] [PMID: 9009995]
[89]
Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 2017; 88(15): 1454-60.
[http://dx.doi.org/10.1212/WNL.0000000000003821] [PMID: 28283597]
[90]
Landon-Cardinal O, Gallay L, Dubourg O, et al. Expanding the spectrum of HIV-associated myopathy. J Neurol Neurosurg Psychiatry 2019; 90(11): 1296-8.
[http://dx.doi.org/10.1136/jnnp-2018-319419] [PMID: 30975823]
[91]
Mandell BF, Calabrese LH. Infections and systemic vasculitis. Curr Opin Rheumatol 1998; 10(1): 51-7.
[http://dx.doi.org/10.1097/00002281-199801000-00008] [PMID: 9448990]
[92]
Barbaro G. Vasculitic syndromes in HIV-infected patients. Adv Cardiol 2003; 40: 185-96.
[http://dx.doi.org/10.1159/000073183] [PMID: 14533554]
[93]
Delgado WA, Almeida OP, Vargas PA, León JE. Oral ulcers in HIV-positive Peruvian patients: An immunohistochemical and in situ hybridization study. J Oral Pathol Med 2009; 38(1): 120-5.
[http://dx.doi.org/10.1111/j.1600-0714.2008.00714.x] [PMID: 19192057]
[94]
Roth DB, McCabe CM, Davis JL. HIV-related occlusive vasculitis. Arch Ophthalmol 1999; 117(5): 696-8.
[http://dx.doi.org/10.1001/archopht.117.5.696] [PMID: 10326977]
[95]
Otedo AE, Oyoo GO, Obondi JO, Otieno CF. Vasculitis in HIV: Report of eight cases. East Afr Med J 2005; 82(12): 656-9.
[PMID: 16619712]
[96]
Ferfar Y, Savey L, Comarmond C, et al. Large-vessel vasculitis in human immunodeficiency virus-infected patients. J Vasc Surg 2018; 67(5): 1501-11.
[http://dx.doi.org/10.1016/j.jvs.2017.08.099] [PMID: 29242069]
[97]
Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1. Ann Intern Med 1999; 130(3): 226-30.
[http://dx.doi.org/10.7326/0003-4819-130-3-199902020-00027] [PMID: 10049201]
[98]
Scotto G, Cibelli DC, Saracino A, et al. Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection. J Infect 2006; 52(4): 294-9.
[http://dx.doi.org/10.1016/j.jinf.2005.05.025] [PMID: 16026843]
[99]
Kosmas N, Kontos A, Panayiotakopoulos G, Dimitrakopoulos A, Kordossis T. Decreased prevalence of mixed cryoglobulinemia in the HAART era among HIV-positive, HCV-negative patients. J Med Virol 2006; 78(10): 1257-61.
[http://dx.doi.org/10.1002/jmv.20695] [PMID: 16927287]
[100]
Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3: 25.
[http://dx.doi.org/10.1186/1750-1172-3-25] [PMID: 18796155]
[101]
Corrado A, Carpagnano GE, Gaudio A, Foschino-Barbaro MP, Cantatore FP. Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine 2010; 77(6): 570-4.
[http://dx.doi.org/10.1016/j.jbspin.2010.02.019] [PMID: 20547086]
[102]
Haustein UF, Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol 1998; 16(3): 353-66.
[http://dx.doi.org/10.1016/S0738-081X(98)00006-6] [PMID: 9642529]
[103]
Iglesias JL, De Moragas JM. The cutaneous lesions of the Spanish toxic oil syndrome. J Am Acad Dermatol 1983; 9(1): 159-60.
[http://dx.doi.org/10.1016/S0190-9622(83)80107-8] [PMID: 6886099]
[104]
Haustein UF, Pustowoit B, Krusche U, Herrmann K. Antibodies to retroviral proteins in progressive scleroderma. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 1993.
[105]
Brudek T, Christensen T, Aagaard L, Petersen T, Hansen HJ, Møller-Larsen A. B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity. Retrovirology 2009; 6: 104.
[http://dx.doi.org/10.1186/1742-4690-6-104] [PMID: 19917105]
[106]
Mihas AA, Abou-Assi SG, Heuman DM. Cutae morphea associated with chronic hepatitis C. J Hepatol 2003; 39(3): 458-9.
[http://dx.doi.org/10.1016/S0168-8278(03)00247-2] [PMID: 12927939]
[107]
Telakis E, Nikolaou A. Localized scleroderma (morphea) in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21(4): 486.
[http://dx.doi.org/10.1097/MEG.0b013e3283229dab] [PMID: 19369835]
[108]
Mosquera JA, Ojea R, Navarro C. HIV infection associated with scleroderma: Report of two new cases. J Clin Pathol 2010; 63(9): 852-3.
[http://dx.doi.org/10.1136/jcp.2010.080044] [PMID: 20819885]
[109]
Okong’o LO, Webb K, Scott C. HIV-associated juvenile systemic sclerosis: A case report. Semin Arthritis Rheum 2015; 44(4): 411-6.
[http://dx.doi.org/10.1016/j.semarthrit.2014.08.005] [PMID: 25245932]
[110]
Dembélé IA, Nyanke NR, Traore D, et al. Scleroderma and HIV infection: A case report with literature review. Open J Int Med 2018; 8(4): 255-60.
[http://dx.doi.org/10.4236/ojim.2018.84024]
[111]
van Dongen CMP, Gijselhart JP, van Gijn J. Behçet and his triad TT - Behçet en zijn trias. Nederlands tijdschrift voor geneeskunde 2012. https://pubmed.ncbi.nlm.nih.gov/23062261
[112]
Dalvi SR, Yildirim R, Yazici Y. Behcet’s Syndrome. Drugs 2012; 72(17): 2223-41.
[http://dx.doi.org/10.2165/11641370-000000000-00000] [PMID: 23153327]
[113]
Wallace GR. HLA-B*51 the primary risk in Behçet disease. Proceedings of the national academy of sciences of the united states of america. https://pubmed.ncbi.nlm.nih.gov/24876276
[114]
Mahajan VK, Sharma NL, Sharma VC, Sharma RC, Sarin S. Behcet’s disease with HIV infection: response to antiretroviral therapy. Indian J Dermatol Venereol Leprol 2005; 71(4): 276-8.
[http://dx.doi.org/10.4103/0378-6323.16623] [PMID: 16394440]
[115]
Ghate JV, Jorizzo JL. Behçet’s disease and complex aphthosis. J Am Acad Dermatol 1999; 40(1): 1-18.
[http://dx.doi.org/10.1016/S0190-9622(99)70523-2] [PMID: 9922007]
[116]
Rizzi R, Bruno S, Dammacco R. Behçet’s disease: An immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997; 27(4): 225-32.
[http://dx.doi.org/10.1007/s005990050002] [PMID: 9506265]
[117]
Greenspan D, Greenspan JS. HIV-related oral disease. Lancet 1996; 348(9029): 729-33.
[http://dx.doi.org/10.1016/S0140-6736(96)02308-2] [PMID: 8806295]
[118]
National Institutes of Health (NIH) Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001; 285(6): 785-95.
[http://dx.doi.org/10.1001/jama.285.6.785] [PMID: 11176917]
[119]
Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. Reumatismo 2014; 66(2): 125-35.
[http://dx.doi.org/10.4081/reumatismo.2014.785] [PMID: 25069494]
[120]
de Menezes EGM, Machado AA, Barbosa F Jr, de Paula FJA, Navarro AM. Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection. J Bone Miner Metab 2017; 35(2): 234-42.
[http://dx.doi.org/10.1007/s00774-016-0749-8] [PMID: 27026434]
[121]
Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39(4): 633-45.
[http://dx.doi.org/10.1016/j.immuni.2013.10.001] [PMID: 24138880]
[122]
Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013; 57(10): 1483-8.
[http://dx.doi.org/10.1093/cid/cit538] [PMID: 23943825]
[123]
Wirz EG, Jaeger VK, Allanore Y, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 2016; 75(7): 1285-92.
[http://dx.doi.org/10.1136/annrheumdis-2015-207271] [PMID: 26232495]
[124]
Womack JA, Goulet JL, Gibert C, et al. Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6(2): e17217.
[http://dx.doi.org/10.1371/journal.pone.0017217] [PMID: 21359191]
[125]
Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93(9): 3499-504.
[http://dx.doi.org/10.1210/jc.2008-0828] [PMID: 18593764]
[126]
Gonciulea A, Wang R, Althoff KN, et al. An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV- men. AIDS 2017; 31(10): 1435-43.
[http://dx.doi.org/10.1097/QAD.0000000000001493] [PMID: 28574962]
[127]
Overton ET, Chan ES, Brown TT, et al. Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A Randomized Trial. Ann Intern Med 2015; 162(12): 815-24.
[http://dx.doi.org/10.7326/M14-1409] [PMID: 26075752]
[128]
Ceballos ME, Carvajal C, Jaramillo J, Dominguez A, González G. Vitamin D and bone mineral density in hiv newly diagnosed therapy-naive patients without any secondary causes of osteoporosis. Calcif Tissue Int 2019; 104(1): 42-9.
[http://dx.doi.org/10.1007/s00223-018-0474-5] [PMID: 30209528]
[129]
Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77(3): 459-74.
[http://dx.doi.org/10.2106/00004623-199503000-00018] [PMID: 7890797]
[130]
Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: A case-control study. J Infect Dis 2001; 184(4): 519-23.
[http://dx.doi.org/10.1086/322779] [PMID: 11471113]
[131]
Taylor LJ. Multifocal avascular necrosis after short-term high-dose steroid therapy. A report of three cases. J Bone Joint Surg Br 1984; 66(3): 431-3.
[http://dx.doi.org/10.1302/0301-620X.66B3.6725356] [PMID: 6725356]
[132]
Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31(6): 1488-92.
[http://dx.doi.org/10.1086/317503] [PMID: 11096017]
[133]
Fessel WJ, Chau Q, Leong D. Association of osteonecrosis and osteoporosis in HIV-1-infected patients. AIDS 2011; 25(15): 1877-80.
[http://dx.doi.org/10.1097/QAD.0b013e32834af637] [PMID: 21785318]
[134]
Alonso CM, Lozada CJ. Effects of IV cyclophosphamide on HIV viral replication in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18(4): 510-2.
[PMID: 10949730]
[135]
Hazarika I, Chakravarty BP, Dutta S, Mahanta N. Emergence of manifestations of HIV infection in a case of systemic lupus erythematosus following treatment with IV cyclophosphamide. Clin Rheumatol 2006; 25(1): 98-100.
[http://dx.doi.org/10.1007/s10067-005-1133-6] [PMID: 16132163]
[136]
Ciuffreda D, Pantaleo G, Pascual M. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation. Transpl Int 2007; 20(8): 649-58.
[http://dx.doi.org/10.1111/j.1432-2277.2007.00483.x] [PMID: 17425723]
[137]
Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19(5): 913-23.
[http://dx.doi.org/10.1016/S0149-2918(97)80045-8] [PMID: 9385480]
[138]
Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17(4): 622-36.
[http://dx.doi.org/10.1016/0149-2918(95)80039-5] [PMID: 8565026]
[139]
Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: Mechanism of action and comparison with zidovudine. Clin Ther 1996; 18(6): 1080-92.
[http://dx.doi.org/10.1016/S0149-2918(96)80063-4] [PMID: 9001825]
[140]
Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118(12): 3263-72.
[http://dx.doi.org/10.1182/blood-2011-01-329060] [PMID: 21576701]
[141]
Feria-Garzón MG, Rugeles MT, Hernandez JC, Lujan JA, Taborda NA. Sulfasalazine as an immunomodulator of the inflammatory process during HIV-1 infection. Int J Mol Sci 2019; 20(18): E4476.
[http://dx.doi.org/10.3390/ijms20184476] [PMID: 31514274]
[142]
Riva DA, Fernández-Larrosa PN, Dolcini GL, Martínez-Peralta LA, Coulombié FC, Mersich SE. Two immunomodulators, curcumin and sulfasalazine, enhance IDV antiretroviral activity in HIV-1 persistently infected cells. Arch Virol 2008; 153(3): 561-5.
[http://dx.doi.org/10.1007/s00705-007-0023-4] [PMID: 18175040]
[143]
Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2(11): 602-10.
[http://dx.doi.org/10.1038/ncprheum0336] [PMID: 17075599]
[144]
Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013; 5: 79-99.
[http://dx.doi.org/10.2147/DHPS.S28801] [PMID: 23569399]
[145]
Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67(5): 710-2.
[http://dx.doi.org/10.1136/ard.2007.081513] [PMID: 18079191]
[146]
Liang S ju, Zheng Q you, Yang Y long, Yang Y, Liu C. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: A case-based review. Rheumatol Int 2017.
[147]
Ofotokun I, Collins LF, Titanji K, et al. Antiretroviral Therapy-induced Bone Loss is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-naïve Persons with HIV Infection: a Phase IIB Trial. Clin Infect Dis 2019.
[http://dx.doi.org/10.1093/cid/ciz1027] [PMID: 31621838]
[148]
Bolland MJ, Horne AM, Briggs SE, et al. 11 Years in HIV-Infected Men. Journal of Bone and Mineral Research. John Wiley & Sons. Ltd 2019; 34: 1248-53.
[149]
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-38.
[http://dx.doi.org/10.1001/jama.296.24.2927] [PMID: 17190893]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy